L
Lyell Immunopharma, Inc. (LYEL)
NMS – Real Time Price. Currency in USD
11.61
-0.88 (-7.05%)
At close: Jun 26, 2026, 4:00 PM EDT
11.85
+0.24 (2.07%)
After-hours: Jun 26, 2026, 5:31 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
11.61
-0.88 (-7.05%)
At close: Jun 26, 2026, 4:00 PM EDT
11.85
+0.24 (2.07%)
After-hours: Jun 26, 2026, 5:31 PM EDT
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual‑targeting CD19/CD20 CAR T‑cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi‑R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Crystal L. Mackall M.D. | Founder & Scientific Advisor |
| Dr. Gary K. Lee Ph.D. | Chief Scientific Officer |
| Dr. Lynn Seely M.D., Ph.D. | Principal Executive Officer, President, CEO & Director |
| Dr. Richard D. Klausner M.D. | Founder & Executive Chairman |
| Mr. Mark A. Meltz J.D. | General Counsel & Corporate Secretary |
| Mr. Stephen J. Hill | Chief Operating Officer |
| Ms. Ann Tomlin | Chief Human Resources Officer |
| Ms. Smital Shah M.B.A. | Principal Financial Officer, CFO & Chief Business Officer |
| Nellie Dillery | Director of Accounting |
| Prof. Stanley R. Riddell M.D. | Founder & Scientific Advisor |
| Date | Type | Document |
|---|---|---|
| 2026-06-15 | 8-K | d102015d8k.htm |
| 2026-05-06 | 8-K | lyel-20260506.htm |
| 2026-05-06 | 10-Q | lyel-20260331.htm |
| 2026-04-24 | DEFA14A | ny20068007x2_defa14a.htm |
| 2026-04-24 | ARS | ny20068007x3_ars.pdf |
| 2026-04-13 | CORRESP | filename1.htm |
| 2026-04-03 | S-3 | d122816ds3.htm |
| 2026-03-12 | S-8 | d121269ds8.htm |
| 2026-03-12 | 10-K | lyel-20251231.htm |
| 2026-03-09 | 8-K | d84786d8k.htm |